Study design and participants
17D-213 yellow fever, yellow fever, yellow fever infection
YELLOW FEVER
This randomised, double-blind, non-inferiority study of 17D-213 yellow fever vaccination in HIV-infected individuals was a substudy of a trial conducted between Nov 6, 2017, and Feb 21, 2018, evaluating all four WHO-prequalified yellow fever vaccines in the general population.Participants were recruited from comprehensive care centres in Mtwapa and Malindi in Kilifi County on the coast of Kenya—17 km and 115 km northeast of Mombasa, respectively. A community engagement plan for the study was developed at each of the comprehensive care centre sites. In this plan, we involved the local subnational health management teams, local administration, comprehensive care providers at the centres, and the members attending the comprehensive care clinics. Potential participants were identified and sensitised for the trial. Willing volunteers provided written informed consent before any study-specific procedures were done to assess their eligibility.Individuals aged 18–59 years, with no contraindication for yellow fever vaccination or previous history of yellow fever infection or vaccination, and with CD4